To further understand the possible mechanism by which ultralow dose DPI reduces colon cancer, we evaluated the activation of tumor-promoting signaling pathways, such as STAT3, MAPK, and NF-κB, in IECs. The gene discussed is NFKB1; the disease is colonic neoplasm.